(BPT) – Do you live with persistent, moderate-to-severe asthma, COPD, allergies, eczema or hives? Inflammation is often a major factor in the severity of your symptoms. It could also be a factor if ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients were aged 40 to 69 years when they were ...

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that ...

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions. Biologics are currently available for asthma management and being studied in ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Asthma and cardiovascular diseases (CVDs) are intricately linked, because of their widespread prevalence ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In those with and those without emphysema, patients ...

Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Meteorin-like protein (Metrnl) is an emerging secreted factor with a multifaceted role in regulating metabolism and modulating inflammatory responses. Initially identified as an adipomyokine, Metrnl ...